Human insulin-like growth factor I (hIGF-I, also called somatomedin C) is a 70 amino acid protein purified from human serum (1) . It is believed to mediate many of the effects of growth hormone; in particular, it has been shown to stimulate growth in hypophysectomized rats (2) . In addition, IGF-I promotes cell growth and differentiation of various cell types (3) . Studies utilizing cDNA and genomic cloning have demonstrated that human IGF-I is produced from larger protein precursors (4) (5) (6) . Two precursors, one of 153 amino acids and one of 195 amino acids, contain the same 70 amino acid IGF-I found in serum but differ in the sequence and length of their carboxyl-terminal extensions (7, 8) .
Human IGF-I shows a remarkable amino acid sequence homology to insulin (1) . This homology is the basis of a computer-generated three-dimensional structural model for hIGF-I (9, 10). This model predicts that a portion of the insulin receptor binding region is conserved within the IGF-I molecule, explaining the ability of hIGF-I to bind to insulin receptors. The model also suggests regions of the hIGF-I molecule that may be responsible for binding to serum carrier proteins.
As a first step in mapping the different binding domains of hIGF-I, we have assembled a synthetic gene for hIGF-I and expressed this gene in cultured mammalian cells. Several previous reports (11) (12) (13) have described the expression of hIGF-I in bacteria. Human IGF-I is produced in Escherichia coli in a denatured, inactive form that must be renatured in vitro (9, 12, 14) . Such manipulations would complicate the interpretation of biological activity of recombinant hIGF-I, especially of structural analogs. Synthesis of a staphylococcal protein A-hIGF-I fusion protein in Staphylococcus aureus results in the secretion of a nondenatured protein, but this procedure requires chemical cleavage to remove the protein A region (13 allow the complementary strands to anneal. The ATP concentration was then adjusted to 1 mM, T4 DNA ligase was added to 0.8 units/10 ,ul, and the reaction mixture was incubated overnight at 15°C. Sections A, B, and C (see Results and Discussion) were purified in a 7 M urea/12% polyacrylamide gel run in 90 mM Tris/90 mM borate/2 mM EDTA. DNA fragments were eluted from the gel and purified on Sep-Pak C18 cartridges, using triethylammonium bicarbonate as described above.
Plasmid Construction and DNA Cloning. Standard procedures for plasmid purification (17) , transformation (18) , and DNA sequencing (19) were used. Large plasmid fragments were separated by agarose gel electrophoresis followed by electrolution and purification on Elutip-d columns. Small DNA fragments (<800 base pairs) were separated by polyacrylamide gel electrophoresis followed by elution in ammonium acetate and purification on Elutip-d columns.
Cell Culture and Transient-Expression Assays. Mouse Lcell fibroblasts (thymidine kinase-negative and adenine phosphoribosyltransferase-negative) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% Nu-serum and 50 ,ug of 2,6-diaminopurine per ml. The mouse L-cell transient-expression assay system using DEAE-dextran has been described (20) . For immunoblot analysis, 200 ,u of cell culture supernatant was concentrated to 40 ,ul and electrophoresed in a NaDodSO4/15% polyacrylamide gel (21) . Following separation in the gel, the proteins were transferred to nitrocellulose filters (22) . The filters were then treated with 0.5% gelatin in phosphate-buffered saline (20 mM sodium phosphate, pH 7.4/0.14 M NaCl/2 mM EDTA) for 1 hr prior to incubation with a 1:100 dilution of anti-IGF antiserum followed by '251-labeled protein A. Autoradiographs were prepared using Kodak XAR film.
Radioimmunoassay. Culture fluids were assayed for hIGF-I by a standard double-antibody radioimmunoassay procedure similar to that previously described (23) . Results obtained are expressed as ng/ml, using [Thr59]hIGF-I as standard.
Binding of '251-labeled IGF-I to Human Placental Membranes. 125I-labeled IGF-I (specific activity, 85 Ci/g) was prepared as described (24) . Freshly obtained placenta was homogenized in 0.25 M sucrose/25 mM benzamidine hydrochloride/S mM EDTA/0.2 mM phenylmethylsulfonyl fluoride in a blender at 4°C. The homogenate was centrifuged at 10,000 x g for 30 min. The supernatant was adjusted to give 0.1 M NaCl and 0.2 mM MgCl2 final concentrations and was centrifuged at 100,000 x g for 1 hr. The 100,000 x g pellet was resuspended in 10 mM Tris HCl, pH 7.5/0.15 M NaCl by homogenization and centrifuged as above. The final pellet was suspended (12 mg of protein per ml) in assay buffer and stored at -70°C. 125I-labeled IGF-I (50 fmol), membranes (0.2 mg), and 20-50 ulI of tissue culture supernatant were incubated at 20°C for 1 hr in 0.2 ml of 0.1 M Hepes, pH 8/120 mM NaCl/5 mM KC1/0.12 mM MgSO4/0.1% bovine serum albumin (BSA). Samples were filtered over Whatman GF/F filters presoaked in 0.1% polyethyleneimine to separate bound from free ligand. The incubation tubes and filters were washed four times with 2.5 ml of cold assay buffer (minus BSA).
Binding of 125I-labeled IGF-I to Acid-Stable Serum Binding
Proteins. Freshly prepared human serum (18 ml) was incubated with 1 M acetic acid for 3 hr at 220C and then centrifuged at 10,000 x g for 20 After 2 hr at -20°C, the precipitates were collected on Whatman GF/F filters and washed five times with 2 ml of ice-cold 70% ethanol. Filters were incubated with 10 ml of Aquasol II (New England Nuclear) for 2 hr before measurement of radioactivity by liquid scintillation counting.
RESULTS AND DISCUSSION
Construction of the Synthetic Gene. A synthetic gene encoding the 70 amino acids of hIGF-I was designed based on the known amino acid sequence (1) . The nucleotide sequence for the gene was selected by optimizing the number of unique restriction endonuclease recognition sites and by avoiding secondary-structure problems. Twenty-two oligonucleotides, ranging in size from 10 to 40 nucleotides, were synthesized, purified, and assembled to form the synthetic hIGF-I gene (Fig. 1) .
To assemble the gene, the oligonucleotides were divided into three sections: A, oligonucleotides 1-9; B, oligonucleotides 10-15; and C, oligonucleotides 16 into cultured mouse fibroblasts, directs the synthesis and secretion of bGH. During the secretion process, the signal peptide of bGH is removed (20) . A derivative of this plasmid, pCMVIE-bGHb, was constructed by moving the EcoRI-Cla I expression cassette from pCMVIE-bGH into EcoRI/Pvu II-digested pBR322 (Fig. 2) . This plasmid has a single Nar I site in exon II of the bGH gene at this junction of the signal peptide and the secreted form of bGH. In order to insert the synthetic hIGF-I gene into the Nar I site of pCMVIE-bGHb, two oligonucleotides were synthesized, IGF-101 (5' CGC-CGGACCGGAGACGCTCTGCGGGGCTGAGCT 3') and IGF-102 (5' CAGCCCCGCAGAGCGTCTCCGGTCCGG 3'). These oligonucleotides were annealed to form a Nar I-Sac I fragment that regenerates the first 10 amino acids of hIGF-I. This manipulation allowed the synthetic hIGF-I gene to be joined to the bGH signal peptide at the Nar I site. The modified hIGF-I gene was inserted between the Nar I and Sma I sites ofpCMVIE-bGHb (Fig. 2) . The resulting plasmid, pCMV-bGH-hIGF, encodes a 97 amino acid fusion protein consisting of the 26 amino acid bGH signal peptide, the first amino acid (alanine) of bGH, and the 70 amino acids of hIGF-I. The amino acid sequence at the junction is the following:
bGH signal hIGF-I
...
Trp-Thr-Gln-Val-Val-Gly-Ala-Gly-Pro-Glu-Thr ...
The expression vector retains the 3' end of the bGH gene that contains the polyadenylylation signal as well as putative transcriptional termination signals (26) . DNA sequence analysis of pCMV-bGH-hIGF confirmed that the predicted hIGF-I coding sequence was inserted (data not shown).
Expression of hIGF-I. Plasmids pCMVIE-bGHb and pCMV-bGH-hIGF were introduced transiently into mouse fibroblasts (L cells) by the DNA/DEAE-dextran sulfate technique (20) . Three days later the cells were rinsed three times in serum-free medium and then incubated an additional 40 hr in serum-free medium. Aliquots of the cell culture medium were analyzed for the presence of hIGF-I by radioimmunoassay, by radioreceptor assay using human placental membranes, and by binding to acid-stable human IGF serum carrier proteins. No IGF-I was detectable by radioimmunoassay or by binding to acid-stable human IGF carrier proteins in conditioned medium from nontransfected L cells or from L cells transfected with the pCMVIE-bGHb vector. Medium from cells transfected with pCMV-bGH-hIGF contained 110 or 190 ng of IGF-I-like activity per ml when measured by radioimmunoassay or serum carrier-protein binding activity, respectively (Table 1) . Small amounts of receptor-active IGF-I-like material were detected in L-cell conditioned medium and in medium from cells transfected with pCMVIE-bGHb (Table 1) . There was a 7-to 14-fold increase in the level of IGF-I measured by radioreceptor assay in cells transfected with pCMV-bGH-hIGF (Table 1) . Since no IGF-I-like activity was detectable in the control media in the other two assays, the apparent receptor binding activity in the controls may be due to an unrelated contaminant in conditioned medium that interferes in the receptor assay. A likely candidate for this interfering contaminant is the tissue-derived IGF binding protein described by DeVroede et al. (27) and Clemmons et al. (28) .
To further characterize the hIGF-I produced by the transiently transformed mouse fibroblasts, the cell culture medium was analyzed by NaDodSO4/polyacrylamide gel electrophoresis followed by immunoblotting using anti-hIGF-I antiserum. Cells transformed by pCMV-bGH-hIGF (Fig. 3,  lane D) Amino acid sequencing of hIGF-I produced by mouse L cells stably transformed with pCMV-bGH-hIGF yields the sequence Ala-Gly-Pro-Glu . . ., indicating that the alanine residue at the junction of the bGH signal peptide and the synthetic hIGF-I gene remains at the amino terminus of the recombinant hIGF-I (M.A.C., unpublished data).
Biological Activity. Previous work showed that IGF-I stimulates DNA synthesis in rat A10 vascular smooth muscle cells (25) . We used this assay to determine the biological activity of our recombinant hIGF-I in conditioned medium from cells transiently transformed with pCMV-bGH-hIGF (Fig. 4) . IGF-I (50 nM) caused a 2-fold increase in [3H]Thymidine incorporation is expressed as the mean + SD of three determinations.
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Proc. Natl. Acad. Sci. USA 84 (1987) cells, which contained 20 nM IGF-I as determined by receptor binding, caused a 2.5-fold increase in DNA synthesis when compared to conditioned medium from nontransfected L cells (Fig. 4) .
In summary, the plasmid pCMV-bGH-hIGF directs the synthesis and secretion of receptor-active and biologically active hIGF-I. This study also suggests that the plasmid pCMVIE-bGHb may be a useful expression vector for the synthesis and secretion of other heterologous proteins in cultured mammalian cells. Mammalian cell culture may be the expression system of choice in order to assure proper secondary and tertiary structure of the protein or when specific posttranslational modifications such as glycosylation, phosphorylation, or amidation are required to produce recombinant proteins with full spectra ofbiological activities.
